Head-to-head comparison
| Property | BPC-157 | GHK-Cu |
|---|---|---|
| Category | Recovery | Skin & Beauty |
| Legal Status | Reclassification Pending | Unregulated |
| Primary Route | subcutaneous | topical |
| Half-life | ~4 hours (estimated) | ~1 hour (plasma) |
| Mol. Weight | 1,419.53 Da | 403.93 Da |
| Side Effects | Nausea (rare), Dizziness, Headache | Injection site irritation, Skin redness (topical), Mild stinging (topical) |
Key differences
- Primary application: BPC-157 targets musculoskeletal and GI tract repair; GHK-Cu targets skin regeneration, collagen remodeling, and anti-aging.
- Structure: BPC-157 is a 15-amino-acid peptide; GHK-Cu is a tripeptide (3 amino acids) complexed with a copper ion.
- Routes: BPC-157 is used subcutaneously, intramuscularly, or orally; GHK-Cu is most commonly applied topically in skincare products, though subcutaneous injection is also used.
- Mechanism: BPC-157 activates the FAK-paxillin pathway and modulates nitric oxide; GHK-Cu activates metalloproteinases, stimulates collagen and glycosaminoglycan synthesis, and attracts immune cells to wound sites.
- Evidence base: BPC-157 has over 100 preclinical studies but no completed human trials; GHK-Cu has both preclinical and published human studies, particularly in dermatology and wound care.
- Availability: GHK-Cu is widely available in cosmetic products (serums, creams) without prescription; BPC-157 is primarily available as a research compound under regulatory review.
- Molecular weight: BPC-157 is 1419.53 Da; GHK-Cu is approximately 340.38 Da, making it small enough for topical absorption.
The verdict
BPC-157 and GHK-Cu serve largely complementary rather than competing roles. BPC-157 is more relevant for deep tissue, tendon, and gut injuries based on its preclinical profile, while GHK-Cu has stronger evidence for skin healing and cosmetic applications including human studies. For skin-related goals, GHK-Cu has more direct evidence; for musculoskeletal repair, BPC-157 is the more studied option.
Frequently asked questions
BPC-157 and GHK-Cu target different aspects of tissue repair through distinct mechanisms and are sometimes combined in protocols addressing both musculoskeletal recovery and skin healing. No clinical studies have evaluated this specific combination.
For surface wound healing and skin repair, GHK-Cu has more direct evidence including published human studies in dermatology. For deep tissue and internal healing (tendons, ligaments, GI tract), BPC-157 has the larger preclinical evidence base.
Yes, GHK-Cu is widely available in cosmetic skincare products (serums, creams, masks) without a prescription. It is one of the few peptides with a robust presence in the consumer cosmetics market.
Yes, GHK-Cu has published human studies, particularly in dermatology and wound care, showing improvements in collagen synthesis, skin thickness, and wound healing. This is a notable advantage over BPC-157, which has only preclinical data.
GHK-Cu is generally considered very well tolerated, especially in topical form. BPC-157 is also reported to have a mild side effect profile (nausea, headache, injection site reactions). Neither has robust long-term human safety data from controlled trials.